Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003, Evolocumab and Alirocumab in CVD Patients, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction (LIBerate-H2H)
Latest Information Update: 31 Mar 2023
At a glance
- Drugs Lerodalcibep (Primary) ; Alirocumab; Evolocumab; HMG-CoA reductase inhibitors
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms LIBerate-H2H
- Sponsors LIB Therapeutics
- 27 Mar 2023 Status changed from active, no longer recruiting to completed.
- 13 Jul 2022 Planned primary completion date changed from 30 Sep 2022 to 30 Aug 2022.
- 13 Jul 2022 Status changed from recruiting to active, no longer recruiting.